Glacier Peak Capital LLC boosted its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,316,993 shares of the medical instruments supplier’s stock after buying an additional 117,418 shares during the period. Harvard Bioscience accounts for approximately 3.6% of Glacier Peak Capital LLC’s portfolio, making the stock its 11th largest position. Glacier Peak Capital LLC owned approximately 3.80% of Harvard Bioscience worth $3,358,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in HBIO. Algert Global LLC raised its stake in shares of Harvard Bioscience by 17.7% in the first quarter. Algert Global LLC now owns 113,818 shares of the medical instruments supplier’s stock worth $296,000 after buying an additional 17,120 shares in the last quarter. Spark Investment Management LLC raised its stake in shares of Harvard Bioscience by 12.8% in the first quarter. Spark Investment Management LLC now owns 116,950 shares of the medical instruments supplier’s stock worth $304,000 after buying an additional 13,250 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in shares of Harvard Bioscience by 29.8% in the first quarter. Essex Investment Management Co. LLC now owns 309,582 shares of the medical instruments supplier’s stock worth $805,000 after buying an additional 71,052 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock worth $1,457,000 after buying an additional 31,300 shares in the last quarter. Finally, Foundry Partners LLC raised its stake in shares of Harvard Bioscience by 2.8% in the second quarter. Foundry Partners LLC now owns 684,775 shares of the medical instruments supplier’s stock worth $1,746,000 after buying an additional 18,575 shares in the last quarter. 62.24% of the stock is currently owned by institutional investors and hedge funds.
Harvard Bioscience, Inc. (NASDAQ HBIO) opened at 3.00 on Friday. The company’s market capitalization is $104.51 million. The firm has a 50-day moving average price of $2.73 and a 200-day moving average price of $2.66. Harvard Bioscience, Inc. has a 1-year low of $2.25 and a 1-year high of $3.30.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by $0.02. The firm had revenue of $25.21 million for the quarter, compared to analyst estimates of $24 million. Harvard Bioscience had a positive return on equity of 1.45% and a negative net margin of 4.37%. On average, analysts forecast that Harvard Bioscience, Inc. will post $0.13 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/19/glacier-peak-capital-llc-purchases-117418-shares-of-harvard-bioscience-inc-hbio.html.
A number of equities research analysts recently issued reports on HBIO shares. Zacks Investment Research raised Harvard Bioscience from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Wednesday, July 12th. TheStreet raised Harvard Bioscience from a “d+” rating to a “c-” rating in a research report on Monday, July 31st. Finally, ValuEngine raised Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $4.75.
In related news, CEO Jeffrey Duchemin acquired 22,000 shares of the stock in a transaction dated Monday, June 12th. The stock was purchased at an average cost of $2.76 per share, with a total value of $60,720.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Earl R. Lewis acquired 12,238 shares of the stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $2.35 per share, with a total value of $28,759.30. The disclosure for this purchase can be found here. Over the last three months, insiders bought 52,950 shares of company stock valued at $135,275. Company insiders own 8.80% of the company’s stock.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
